Description
Cablivi (caplacizumab) is a prescription medication used to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder that causes blood clots to form in small blood vessels throughout the body. The medication is administered by intravenous injection.
Uses:
Cablivi works by blocking the binding of von Willebrand factor to platelets, which reduces the formation of blood clots in small blood vessels. In patients with aTTP, Cablivi helps to prevent the formation of blood clots and reduces the time needed to normalize platelet counts. Cablivi is used in combination with plasma exchange and immunosuppressive therapy to treat aTTP.
Storage Conditions:
Cablivi should be stored in a refrigerator at 2°C to 8°C. The medication is stable for up to two years when stored in the original packaging.
Mechanism of Action:
Cablivi binds to the A1 domain of von Willebrand factor and blocks its interaction with platelet glycoprotein Ib/IX/V complex, which reduces the formation of blood clots in small blood vessels. By inhibiting the binding of von Willebrand factor to platelets, Cablivi helps to prevent the formation of blood clots in patients with aTTP.
HOW TO USE:
Cablivi is administered by intravenous injection under the supervision of a healthcare professional. The recommended dosage is an initial 11 mg intravenous loading dose, followed by daily 11 mg subcutaneous injections for the duration of plasma exchange treatment. The duration of treatment with Cablivi may be adjusted based on the patient’s response.
Precautions:
• Cablivi should not be used to treat thrombotic thrombocytopenic purpura caused by other underlying conditions.
• The most common adverse reactions reported with Cablivi use include bleeding and headache.
• Patients should inform their healthcare provider of all medications, supplements, or herbal products they are taking before starting treatment with Cablivi.
Drug Interactions:
Cablivi has not been studied in patients taking anticoagulant medications other than aspirin. However, Cablivi may interact with other medications that affect blood clotting. Patients should inform their healthcare provider of all medications they are taking before starting treatment with Cablivi.
Contraindications:
• Cablivi should not be used in patients with a history of hypersensitivity to Cablivi or any of its components.
• The safety and efficacy of Cablivi have not been established in pediatric patients.
Overdose:
There is no specific treatment for Cablivi overdose; patients who have received an overdose should be monitored for adverse reactions.
Adverse Reactions:
The most common adverse reactions reported with the use of Cablivi include bleeding and headache. Patients should inform their healthcare provider of any unusual or unexpected reactions while using Cablivi.
In conclusion, Cablivi (caplacizumab) is a medication used to treat acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy. The medication is administered by intravenous injection and works by blocking the binding of von Willebrand factor to platelets, reducing the formation of blood clots in small blood vessels. Cablivi should be stored in the refrigerator at 2°C to 8°C and is stable for up to two years. Patients with a hypersensitivity to Cablivi or any of its components should not receive the medication. Cablivi may interact with other medications affecting blood clotting, so patients should inform their healthcare provider about any medications they are taking before starting Cablivi treatment. Adverse reactions, such as bleeding or headache, are commonly reported. Patients should consult their healthcare provider if they experience any unusual responses.
Reviews
There are no reviews yet.